Drug-induced liver injury (DILI) remains a major challenge in medicine, with acetaminophen (APAP) toxicity accounting for nearly 50% of acute liver failure cases in some regions. Early and precise detection is key to improving drug safety and patient care.
At Mecwins, we are actively working on the detection of miR-122-5p, a liver-specific biomarker released into the bloodstream upon hepatocyte damage. miR-122-5p provides an earlier and more specific signal of liver injury than traditional markers like alanine aminotransferase (ALT) and aspartate aminotransferase (AST), allowing for faster and more accurate diagnosis.
Additionally, we are integrating interleukin 6 (IL-6) measurement to enhance DILI assessment. While miR-122-5p directly indicates liver damage, IL-6 reflects the inflammatory response, offering complementary insights. The combination of these biomarkers in a single assay allows for a more comprehensive evaluation of liver injury, improving differentiation between damage mechanisms and enabling more precise clinical interventions.
At Mecwins, we are collaborating closely with Destina Genomics to further refine and enhance our detection capabilities. Our work represents a significant advancement in DILI detection, contributing to the development of more effective diagnostic tools and improving drug safety. Stay tuned for more updates on our progress and upcoming breakthroughs in liver injury detection.
